Safety of @entity968 for the treatment of chronic @entity1142 in XXXX .

@entity1 @entity2464 @entity1142 @entity493 @entity970 @entity968
OBJECTIVES: To assess the clinical and biochemical safety profile of long-term @entity968 ( @entity970 ) therapy in @entity1 with chronic @entity1142 and to assess pediatric @entity1 acceptance of @entity970 therapy. DESIGN: Prospective observational study. SETTING: Pediatric clinics at a referral center. @entity1 Eighty-three @entity1 (44 with chronic @entity1142 , 39 with @entity1142 and @entity2464 ) receiving @entity970 therapy for more than 3 months. MAIN OUTCOME MEASURES: Clinical adverse effects related to @entity970 therapy and acceptance and compliance with @entity970 therapy. Serum electrolyte levels, osmolality, albumin levels, and liver and renal function test results were measured. RESULTS: At the time of evaluation, the mean duration of @entity970 therapy was 8.7 months, and the mean @entity970 dose was 0.75 g/kg daily. There were no major clinical adverse effects. All blood test results were normal, except for transient minimal @entity493 aminotransferase elevation unrelated to therapy in 9 @entity1 . All @entity1 preferred @entity970 to previously used laxatives, and daily compliance was measured as good in 90% of @entity1 . CONCLUSIONS: Long-term @entity970 therapy is safe and is well accepted by @entity1 with chronic @entity1142 with and without @entity2464 .
